Keyword: U.S. Federal Trade Commission
Ending the sale to Aurobindo marks a hiccup in Novartis' plan to focus more on higher-margin innovative medicines.
Mylan and Pfizer have already postponed the close of their generic merger amid COVID-19 concerns. Now the pair is hoping to speed up EU review.
With COVID-19 hamstringing regulatory reviews, Pfizer and Mylan have delayed the close of their megamerger until the second half of 2020.
With only the Federal Trade Commission left to clear in their $63 billion merger, AbbVie and Allergan may face a delay due to the novel coronavirus.
Waiting expectantly for U.S. approval of their $63 billion merger, AbbVie and Allergan received a final nod from the EU after offloading two assets.
Allergan was willing to part with candidate brazikumab to pass FTC muster, but union and consumer groups say that sale won't amend antitrust worries.
The FDA and the FTC recently released a joint statement noting their intent to carefully monitor biologic and biosimilar marketing.
Currently serving a stint in federal prison after a fraud conviction, Martin Shkreli faces a new suit over his company's anticompetitive practices.
After months of regulatory scrutiny, the EU has given AbbVie and Allergan's $63 billion merger its first go-ahead in anticipation of an FTC decision.
Roche's $4.3 billion Spark Therapeutics deal is a poster child for extra antitrust scrutiny on biopharma M&As in 2019.